Stocks · News reference
Filed: 2026-08-03 AccNo: 0001193125-26-330810 Size: 5 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 3.03: Material Modifications to Rights of Security Holders Item 4.01: Changes in Registrant's Certifying Accountant Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
Read original at benzingaAnalysts change outlook on top Wall Street names, including initiations, upgrades, and downgrades. Check our analyst ratings page for details.
Read original at benzingaObsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell
Read original at benzingaPiper Sandler analyst Kelsey Goodwin initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Overweight rating and announces Price Target of $42.
Read original at benzinga